Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for NovaBay Pharmaceuticals, Inc. (NBY:NYSE), powered by AI.
NovaBay Pharmaceuticals, Inc. is currently trading at $1.11. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for NovaBay Pharmaceuticals, Inc. on Alpha Lenz.
NovaBay Pharmaceuticals, Inc.'s P/E ratio is -0.0.
“NovaBay Pharmaceuticals, Inc. trades at a P/E of -0.0 (undervalued) with strong ROE of 199.6%.”
Ask for details →NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development and commercialization of non-antibiotic anti-infective consumer products. It primarily operates in the field of eye care under the proprietary name Avenova®, which is a lid and lash hygiene product designed to maintain ocular health and comfort. The company places a strong emphasis on innovation within the pharmaceutical landscape, focusing on solutions that address prevalent health issues without relying on traditional antibiotics, thereby contributing to the significant global effort in combating antibiotic resistance. Operating in the healthcare sector, NovaBay Pharmaceuticals is pivotal in delivering effective consumer-friendly health solutions, catering to both the general public and healthcare professionals. Besides ophthalmology, its product lines also extend into dermatology, with offerings that provide relief and treatment for various skin conditions. Based in California, NovaBay Pharmaceuticals continues to enhance its market presence through strategic partnerships and direct consumer sales, reinforcing its commitment to improving health standards and responding dynamically to evolving medical needs.
“NovaBay Pharmaceuticals, Inc. trades at a P/E of -0.0 (undervalued) with strong ROE of 199.6%.”
Ask for details →NovaBay Pharmaceuticals, Inc. (ticker: NBY) is a company listed on NYSE in the Healthcare sector (Biotechnology). It has approximately 13 employees. Market cap is $1M.
The current price is $1.11 with a P/E ratio of -0x and P/B of -0x.
ROE is 199.63%.